Immune Repertoire Assays for Hemato-Oncology Research

Lymphoid malignancies involve the clonal proliferation of one or more B or T cells. Every B and T cell expresses distinct receptors on its surface, which give rise to a vastly diverse immune repertoire. Using next-generation sequencing (NGS) technology, these unique receptor sequences can be used to assess clonality, detect rare clones, and measure somatic hypermutation (SHM).

NGS offers significant advantages over traditional approaches by providing sequence information, giving a more detailed view into repertoire (sub-clonal and intra-clonal) diversity, offering ultra-high sensitivity, and providing greater flexibility to multiplex.



GenomeWeb On-Demand Webinar

Advances in Immune Repertoire Sequencing for the Study of Lymphoid Neoplasms

Learn about the value of immune repertoire sequencing in hematological oncology research applications. Dr. DeCoteau
will share his experience using the new Oncomine
Pan-Clonality assays.




Dr. John DeCoteau MD, FRCPC
Professor Pathology and Laboratory Medicine
Advanced Diagnostic Research Laboratory
University of Saskatchewan



Clonality and Rare
Clone Detection

NGS provides sequence-level resolution for clonality assessment, allowing you to detect expanded clones from poly-clonal samples with very high specificity. Integrated bioinformatic tools let you easily assess clonal lineage to better understand the relationship between two clones.

NGS offers a greater level of sensitivity when compared to traditional methods like flow cytometry. The ultralow limit of detection (LoD) of 10-6 (1 in 1,000,000 cells) enables you to detect extremely rare clones that traditional less-sensitive methods can miss.

Using proprietary Ion AmpliSeq™ technology, Oncomine™ immune repertoire assays can target multiple immune receptors in a single reaction, which can lead to increased positive clonality detection rates (>90%) and reduce the need for
secondary testing. 


Oncomine Pan-Clonality Assays

Somatic Hypermutation

Following V(D)J recombination in developing lymphocytes, the IGHV gene undergoes somatic hypermutation. During this process, a series of point mutations are introduced to help confer greater repertoire diversity and enable higher affinity for
potential antigens.

The degree of somatic hypermutation is a key biomarker relevant for chronic lymphocytic leukemia (CLL) research. Long-amplicon NGS assays provide highly accurate IGHV SHM quantification, while enabling efficient batch sample processing and simplifying the workflow when compared to traditional Sanger Sequencing methods.



Powerful informatics and visualization tools

Interactive spectratyping plots make it easy to identify clonal expansion within the broader context of the repertoire. Automated reporting features provide detailed information on each clone, including the CDR3 sequence, SHM frequency, clone frequency, and more.


Scientific Posters

View our posters from the 2022 American Association of Cancer Research (AACR) Meeting

EAHP 2021 Hemato-Oncology Symposium

Watch this on-demand presentation to hear our customers discuss the latest advancements in NGS testing for
lymphoid neoplasm samples.



63rd ASH Poster Presentations

Watch our on demand poster presentations below to learn how we can help simplify your path to answers
in the study of myeloid and lymphoid cancers.



Additional Resources

Get More Information

Request a quote or personal demonstration from a Thermo Fisher Representative.



For Research Use Only. Not for use in diagnostic procedures.